Invasive fungal infections market outlook highlighting key growth drivers

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Invasive Fungal Infections Market Expected To Change From 2026 To 2030?

The invasive fungal infections market has experienced a consistent increase in size recently. It is projected to expand from $7.91 billion in 2025 to $8.24 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.1%. Historically, this expansion was driven by factors such as the increasing prevalence of HIV and cancer patients, the widespread application of broad-spectrum antibiotics, the established use of amphotericin b in hospital settings, a rise in organ transplant procedures, and a heightened incidence of hospital-acquired fungal infections.

The invasive fungal infections market is projected to experience substantial growth in the upcoming years, with its size anticipated to reach $10.1 billion by 2030, progressing at a compound annual growth rate (CAGR) of 5.2%. This expansion during the forecast period can be attributed to factors such as the development of novel antifungal drug classes, a heightened awareness regarding antifungal resistance, the enlargement of critical care infrastructure, improved diagnostic capabilities for fungal infections, and increasing investment into infectious disease research. Significant trends identified for the forecast period include a rising incidence of invasive fungal infections among immunocompromised patients, the growing adoption of echinocandins as a primary therapeutic option, an expanded utilization of combination antifungal treatment strategies, the proliferation of hospital-based antifungal stewardship programs, and an increasing demand for broad-spectrum and targeted antifungal agents.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13189&type=smp

What Major Factors Are Driving The Invasive Fungal Infections Market Forward?

An increasing number of individuals afflicted with the human immunodeficiency virus (HIV) is anticipated to drive the expansion of the invasive fungal infection market in the future. Human Immunodeficiency Virus (HIV) infection is characterized by a virus that impairs the immune system, reducing its capacity to combat diseases and illnesses. A growing population with weakened immune systems, for instance due to Human Immunodeficiency Virus (HIV) or acquired immunodeficiency syndrome (AIDS), heightens vulnerability to invasive fungal infections. This, in turn, opens avenues for manufacturers to innovate and provide specialized, more potent antifungal medications. To illustrate, data from July 2025 by the Joint United Nations Programme on HIV/AIDS (UNAIDS), an international organization based in Switzerland, indicated that 40.8 million [37.0 million–45.6 million] individuals were living with HIV in 2024. During the same year, approximately 1.3 million [1 million–1.7 million] people contracted new HIV infections, and 630 000 [490 000–820 000] fatalities were attributed to AIDS-related conditions. Consequently, the increase in the number of people living with human immunodeficiency virus (HIV) is projected to stimulate the expansion of the invasive fungal infection market.

How Is The Invasive Fungal Infections Market Categorized Across Its Segment Groups?

The invasive fungal infections market covered in this report is segmented –

1) By Disease Type: Candidemia And Invasive Candidiasis, Intra Abdominal Candidiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Other Disease Types

2) By Drug Type: Polyenes, Triazoles, Echinocandins, Flucytosine, Other Drug Types

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Candidemia And Invasive Candidiasis: Bloodstream Infections, Disseminated Candidiasis

2) By Intra-Abdominal Candidiasis: Peritoneal Candidiasis, Abscess Formation

3) By Cryptococcal Meningitis: Primary Cryptococcal Meningitis, Secondary Cryptococcal Meningitis

4) By Esophageal Candidiasis: Acute Esophageal Candidiasis, Chronic Esophageal Candidiasis

5) By Histoplasmosis Acute Pulmonary: Disseminated Histoplasmosis, Chronic Pulmonary Histoplasmosis

6) By Other Disease Types: Aspergillosis, Mucormycosis, Other Rare Fungal Infections

Which Trends Are Impacting The Progress Of The Invasive Fungal Infections Market?

Leading companies in the invasive fungal infection market are concentrating on advanced products, including Zisavel capsules, to heighten treatment efficacy, improve patient outcomes, and expand accessibility for individuals impacted by serious fungal infections. Zisavel capsules are a generic antifungal medication, derived from isavuconazole, specifically developed to combat invasive aspergillosis and mucormycosis. These 100 mg capsules endeavor to offer an affordable alternative for patients, thus improving access to effective care. For example, in October 2023, BDR Pharmaceuticals, an India-based generic and specialty pharmaceutical company, introduced Zisavel Capsules, a generic antifungal drug, for treating invasive aspergillosis and mucormycosis. Zisavel is indicated for managing invasive aspergillosis and mucormycosis, both severe fungal infections that can be life-threatening. The launch of Zisavel aims to enhance treatment accessibility for patients by significantly reducing costs compared to current options like voriconazole and posaconazole.

Which Firms Are Influencing Competition In The Invasive Fungal Infections Market?

Major companies operating in the invasive fungal infections market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., BioMarin Pharmaceutical Inc., Xellia Pharmaceuticals, Basilea Pharmaceutica, Cidara Therapeutic Inc., Pulmocide Ltd., NovaBiotics Ltd, F2G Ltd., Giner Inc., Ciron Drugs And Pharmaceuticals Pvt. Ltd., Hexima Limited, Scynexis Inc., Enzon Pharmaceuticals Inc., Matinas BioPharma Holdings Inc., Biosergen AB

Get The Full Invasive Fungal Infections Market Report:

https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report

Which Region Is The Largest In The Invasive Fungal Infections Market?

North America was the largest region in the invasive fungal infections market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the invasive fungal infections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Invasive Fungal Infections Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report

Browse Through More Reports Similar to the Global Invasive Fungal Infections Market 2026, By The Business Research Company

Systemic Aspergillosis And Systemic Candidiasis Market Report 2026

https://www.thebusinessresearchcompany.com/report/systemic-aspergillosis-and-systemic-candidiasis-global-market-report

Invasive Fungal Infections Market Report

https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report

Fungal Protein Market Report

https://www.thebusinessresearchcompany.com/report/fungal-protein-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795